knee osteoarthritis

Gefapixant (AF219) is a P2X3 receptor (P2X3R) antagonist with IC50 of ~30 nM at recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors.

ADL-5747 (ADL-5747 (free base)) (free base) is a delta opioid receptor agonist used in the treatment of neurological disorders, skin and musculoskeletal disorders, and may be used in the study of postherpetic neuralgia, knee osteoarthritis and pain.

Strontium ranelate (S12911), a strontium (II) salt of the ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in the treatment of severe osteoporosis.

(Z)-Capsaicin (Zucapsaicin) is a medication used to treat osteoarthritis of the knee and Others neuropathic pain.(Z)-Capsaicin is a synthetic cis isomer of natural capsaicin that has shown therapeutic efficacy in pain accompanying osteoarthritis of the knee.

Funapide (TV 45070) is a potent Sodium Channel Nav1.7 inhibitor with potential anti-inflammatory activity for the treatment of erythema gangrenosum, musculoskeletal pain, knee osteoarthritis, and postherpetic nerves.

Adavivint, also known as SM04690, is a small-molecule inhibitor of the Wnt pathway which is being investigated as a potential disease modifying agent for the treatment of osteoarthritis of the knee

Cindunistat( PHA-728669F, PF-00572986, PHA-84250, SD-6010, and SC-084250) is a potent and oral selective iNOS inhibitor which is expected to be used in patients with symptomatic osteoarthritis of the knee.

Aldumastat (GLPG1972) is a highly potent, specific and orally active inhibitor of ADAMTS-5.Aldumastat is used for the study of osteoarthritis of the knee.

Nadecnemab is an IGG4-κantibody targeting GFRA3, a receptor of the glial cell-derived neurotrophic factor family. Nadecnemab can be used for knee osteoarthritis and neurological disorders.

Fasinumab (Anti-Human NGF), a human IgG1κ monoclonal antibody targeting nerve growth factor (NGF), can be used in studies about acute sciatica and knee osteoarthritis (OA). clinical research has demonstrated that Fasinumab achieves statistically significant improvements in both pain and physical function scores when compared to a placebo control group.

Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.